Lund, Sweden, 14 January 2016 – NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces the partial acquisition of British company Isomerase Therapeutics (“Isomerase”) with the overall goal to strengthen the partnership and accelerate NeuroVive’s research and development (R&D) program. The acquisition aims to further enhance the collaboration and to ensure that NeuroVive’s projects remain a key priority for Isomerase. Furthermore, the partnership will support the discovery of new compounds, based on the additional expertise Isomerase brings to the partnership. This is a key step forward for NeuroVive, who are committed to advancing the R&D portfolio as quickly as possible. Most recently, the joint teams at NeuroVive and Isomerase have been able to advance the drug candidate process for the Complex I program (NVP015) and the project is progressing well. “We highly value our strong partnership with the team at Isomerase and want to ensure we remain aligned on project priorities moving forward. Isomerase brings additional expertise to the table which supports our R&D efforts and allows us to both accelerate our current R&D program as well as identify new compounds to fuel our future portfolio” said Jan Nilsson, interim CEO of NeuroVive Pharmaceutical. “Through our collaboration with Isomerase, our discovery platform for complex I deficiency has already seen advancements through the generation of new molecules and we expect to further progress this project as the aim is to select a drug candidate for preclinical development in 2016” continued Jan Nilsson. Isomerase is a world leader in the discovery and development of molecules that target peptidyl-prolyl isomerases such as cyclophilins. The team is actively involved in the pharmacology, chemistry and manufacturing for many of NeuroVive’s projects. "We have built up a very strong relationship with the team at NeuroVive over the last couple of years and this partial acquisition is a natural extension of this. It will enable us to take part in the future success of NeuroVive’s exciting early stage projects and in return give NeuroVive confidence that we are fully engaged with our excellent collaboration. We also hope that it will enable NeuroVive to access future returns on our new ground-breaking drug discovery technologies and our own early stage in-house drug discovery projects." said Matt Gregory, CEO of Isomerase Therapeutics. The acquisition will be executed in two steps. The first step in the acquisition was executed on January 13, 2016 when NeuroVive acquired approximately 5% shares in Isomerase with payment in own shares. The next step in the acquisition will be completed later this year where NeuroVive will acquire approximately 5% further of the shares in Isomerase as a cash payment of 550 000 GBP. In order to make payment for the shares in Isomerase acquired January 13, 2016, the NeuroVive board of directors approved the same day, with prior authorization from the AGM on March 30 2015, the issue of 738,533 new shares. The purchase price for the first step amounting to approximately 6.8 million was based on the average closing price of NeuroVive shares on Nasdaq Stockholm from 23 December 2015 to January 12, 2016 inclusive. The Non-Cash Consideration increases the number of shares of NeuroVive with an additional 738,533 shares from 30,735,152 shares to 31,473,685 shares in total and increases the share capital by SEK 36,926.65 from SEK 1,536,757.60 to SEK 1.573.684.25 in total. The Non-Cash Consideration entails a dilution of approximately 2.4%. About NeuroVive NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, is committed to the discovery and development of highly targeted candidates that preserve mitochondrial integrity and function in areas of therapeutic need. NeuroVive’s business approach is driven by value-adding partnerships with leading research institutions and commercial partners across the globe. NeuroVive’s portfolio consists of two clinical projects in acute kidney injury (AKI) and traumatic brain injury (TBI) with candidates in clinical and preclinical development and two drug discovery platforms. NeuroSTAT® has orphan drug status in Europe and in the US for treatment of moderate to severe traumatic brain injury and is currently being evaluated in a Phase II study (CHIC). CicloMulsion® is being evaluated in an ongoing Phase II study (CiPRICS) in acute kidney injury during major surgery. NeuroVive’s shares are listed on Nasdaq Stockholm, Sweden. For investor relations and media questions, please contact: Johannes Nebel, Laika Consulting, Tel: +46 (0)735 81 71 68 or ir@neurovive.com It is also possible to arrange an interview with NeuroVive’s interim CEO Jan Nilsson at the above contacts. NeuroVive Pharmaceutical AB (publ) Medicon Village, SE-223 81 Lund, Sweden Tel: +46 (0)46 275 62 20 (switchboard), Fax: +46 (0)46 888 83 48 info@neurovive.com (info@neurovive.com), www.neurovive.com NeuroVive Pharmaceutical AB (publ) is required to publish the information in this news release under The Swedish Securities Market Act. The information was submitted for publication on the 14 January 2016, at 08.30 CET.
NeuroVive buys stake in Isomerase Therapeutics Lund,
Top 10 Most Recent News Articles
ECRI Welcomes Safety Expert Meshkati to Its Board
The Safety Maverick Steps into Healthcare They've gone and done it—appointed a rockstar of systems safety to ECRI's Board of Trustees. Professor Najmedin Meshkati, who's practically been around every major industrial accident of the past few decades, is about to shake things up. Imagine the guy who's dissected calamities like the BP Texas City Refinery explosion and the...
Continue Reading
Argo Biopharma's BW-20805 Shows Promise in HAE Phase II Trial
Argo's Gains in Hereditary Angioedema Therapy Think about it, folks – reducing a hereditary angioedema attack by over 80%? Argo Biopharma, the slick operator in the RNA therapeutics space, is flexing its muscles again. They've hauled in some impressive data for their siRNA therapeutic, BW-20805, at the 2026 Bradykinin Symposium in Berlin. For you deep-pocketed investors...
Continue Reading
Regeneron: Investors Face Class Action Over Study Flaws
Regeneron Investors Grit Teeth Amid Lawsuit Drama The gloves are off in the pharmaceutical battleground, folks. Investors who thought they were riding the big wave with Regeneron Pharmaceuticals (NASDAQ: REGN) are now staring down the barrel of a class action lawsuit. It seems the company’s been caught in a storm of legal action following allegations of misleading...
Continue Reading
Aurzen Leverages Basquiat for Art-Infused Projection Line
A Fresh Perspective on Portable Projection If anyone had told me a tech brand would buddy up with the world of fine art to launch a new gadget line, I'd have raised an eyebrow. But here we are, shrugging away the standard and looking at what's cooking over at Aurzen. The company's new initiative, 'Unfold the Art,' marries the magnetism of Jean-Michel Basquiat's artwork...
Continue Reading
Windows Storage Trends Shift: SSD Dominates 2026
SSDs Take Center Stage in Storage Evolution Howdy, storage folks! It's 2026, and one thing's for sure—SSDs are strutting their stuff at the top of the storage heap. According to the latest report by EaseUS Software, the dominant drive isn't about sheer size anymore. We've moved on to smarter space management. Now hear this: 79.73% of Windows system drives are rocking...
Continue Reading
PinkBlush Maternity Unveils Its 2026 Fall Fashion Line
Elevating Maternity Fashion with PinkBlush's Fall 2026 Line You know, it's not every day you see maternitywear aiming to push the envelope, but that's exactly what PinkBlush is doing this fall. They've unleashed their Fall 2026 collection, and let's just say, it's less about the frills and more about redefining what expecting mothers can expect from the fashion world. A...
Continue Reading
Ed Markey's Political Future on Shaky Ground in MA
Massachusetts Voters Voice Desire for Change Ever seen an old engine stutter and cough before finally quitting? That's what Ed Markey's political career is starting to feel like. A fresh poll has surfaced, casting doubt over his steady grip on his longstanding Senate seat in Massachusetts. People are yearning for fresh faces and new ideas like never before. It's as if the...
Continue Reading
Reolink Unveils OMVI 2i Ultra at IFA 2026
Reolink's Bold Move Into the Future of Home Security Amidst the hustle of Berlin's IFA 2026, Reolink dropped its latest gem: the OMVI 2i Ultra—an all-in-one security powerhouse promising to change the game for home protection junkies. As usual, Reolink's got its eyes on the prize, pushing boundaries with this latest lineup. OMVI 2i Ultra: Dual-View Revolution If you've...
Continue Reading
Baidu Joins Shanghai-HK Connect, Expanding Reach
Big News from Baidu: Connect Program Inclusion Bet you didn't see this one coming. Baidu, the titan of AI in China, just rolled out some significant buzz. Starting September 7th, their Class A ordinary shares will join the Shanghai-Hong Kong Stock Connect program, shaking things up on the Shanghai Stock Exchange. This move is set to give investors from the Chinese...
Continue Reading
ACEMAGIC Unveils New AI Mini Workstation at IFA 2026
A Glimpse Into ACEMAGIC's Latest Innovation Look if you had told me five years ago that AI mini workstations would be making waves, I'd have probably smirked. Yet, here we are; ACEMAGIC is setting the stage at IFA 2026 in Berlin with their fresh-out-the-oven F9A AI mini workstation, powered by AMD's Ryzen AI Max+ PRO 495 processor. It all goes down from September 4 to 8...
Continue ReadingTop 5 Most Recently Viewed Articles
Fosun Pharma's 2024 Annual Results: Growth and Innovation Highlights
Fosun Pharma Reports 2024 Annual Results Accelerating Globalization and Innovation in Healthcare Shanghai Fosun Pharmaceutical (Group) Co., Ltd., known as Fosun Pharma, has made impressive strides in its business with a clear focus on innovative healthcare solutions. The company has announced remarkable annual results with a significant operating cash flow increase of...
Continue Reading
Ultra Clean Holdings Launches $400 Million Convertible Notes
Shifting Tactics in the Market In a surprising move last week, Ultra Clean Holdings (NASDAQ: UCTT) announced plans for a substantial $400 million offering of convertible senior notes. While many companies are tightening their belts, Ultra Clean is out here pushing the envelope, gearing up for a notable positioning shift that could rattle both investors and competitors...
Continue Reading
Century Complete Launches Cottages of Crestview, FL
Cottage-Style Living in Crestview Takes Center Stage Mark your calendar, folks! June 6 is set to be a big day for anyone seeking a slice of the affordable homeownership pie in Crestview, Florida. Century Communities, Inc. (NYSE: CCS) rolls out the welcome mat for the Grand Opening of the Cottages of Crestview. This move signifies more than just a new housing project; it's...
Continue Reading
Lantheus Investors Alert: Investigations by Faruqi & Faruqi
Faruqi & Faruqi Investigates Lantheus Holdings, Inc. Faruqi & Faruqi, LLP is actively looking into potential claims on behalf of investors who may have suffered losses from their investments in Lantheus Holdings, Inc. This national securities law firm holds an impressive record of recovering substantial amounts for investors since its inception in 1995. Investor Outreach...
Continue Reading
Clear Street's Recognition in Technology and Client Services Tops Industry Charts
Clear Street Celebrates Major Industry Recognition Clear Street, a cutting-edge financial technology firm, has recently garnered significant accolades within the brokerage space. These awards recognized the company's exceptional innovations and client services, underscoring its commitment to transforming the brokerage ecosystem. Highlights from the Global Custodian Awards...
Continue Reading